gorodenkoff/iStock via Getty Images
Biophytis SA (OTCPK:BPTSY) Tuesday unveiled its strategic outlook for the year and said that 2025 will be decisive for the company, with several major initiatives to accelerate the clinical development of BIO101 (20-Hydroxyecdysone) and its commercialization.
Biophytis will actively pursue
